---
created: 2025-04-13
updated: 2025-04-13T10:53
id: FaR@$s;D<u
specialty: hemato
specialty_id: 170
tags:
  - source/ak-original-decks::step-2::cheesy-dorian-(m3)
  - "source/ak-step2-v11::!shelf:": 
  - theme/cards-anking-skipped
  - source/ak-step2-v11::!shelf::im::no-dupes
  - source/ak-step2-v11::!shelf::im::no-dupes::only-step2
  - "source/ak-step2-v11:": 
  - source/ome-banner
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::uw::heme/onc::heme/onc-dorian
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::uw::heme/onc::heme/onc-zanki
  - "source/ak-step2-v11:": 
  - theme/subjects::immunology-&-pathology::02-immunology::hypersensitivity::transfusion-reaction
  - "source/ak-step2-v11:": 
  - theme/subjects::immunology-&-pathology::02-immunology::hypersensitivity::transfusion-reaction::febrile-nonhemolytic-transfusion-reaction
  - source/ak-step2-v11::original-decks::dorian::im::uw::heme/onc
  - source/ak-step2-v11::original-decks::zanki-step-2::im::hemeonc"
type: flashcard
---

# Question
What is the recommended RBC pre-treatment for a patient who will receive a transfusion of pRBCs and has a history of febrile non-hemolytic transfusion reaction?   **Leukoreduction**

---

# Answer
removes the leukocytes that are the source of cytokines; also useful for reducing risk of CMV transmission and HLA alloimmunization